Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem
about
Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureusWhole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureusDissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association.Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureusControl of the Staphylococcus aureus toxic shock tst promoter by the global regulator SarA.Site-specific mutation of Staphylococcus aureus VraS reveals a crucial role for the VraR-VraS sensor in the emergence of glycopeptide resistance.The sensor histidine kinase RgfC affects group B streptococcal virulence factor expression independent of its response regulator RgfA.Novel Mutation Sites in the Development of Vancomycin- Intermediate Resistance in Staphylococcus aureus.Bacterial stress responses as determinants of antimicrobial resistance.Glycopeptide antibiotics: back to the future.Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.Antimicrobial heteroresistance: an emerging field in need of clarity.Impact of Time to Appropriate Therapy on Mortality in Patients with Vancomycin-Intermediate Staphylococcus aureus Infection.Targeting bactoprenol-coupled cell envelope precursors.Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureusEpigallocatechin gallate induces upregulation of the two-component VraSR system by evoking a cell wall stress response in Staphylococcus aureus.Population Genomics of Reduced Vancomycin Susceptibility in Staphylococcus aureus.Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus.An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.In Vitro Tolerance of Drug-Naive Staphylococcus aureus Strain FDA209P to Vancomycin."Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.Mutation of RNA polymerase β-subunit gene promotes heterogeneous-to-homogeneous conversion of β-lactam resistance in methicillin-resistant Staphylococcus aureuswalK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.VraR Binding to the Promoter Region of agr Inhibits Its Function in Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA.Reduced vancomycin susceptibility in porcine ST9 MRSA isolates.Rapid and easy detection of low-level resistance to vancomycin in methicillin-resistant Staphylococcus aureus by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
P2860
Q28078930-B53D89EF-EB0A-4BAF-8BD8-BA62B5683B7EQ28478770-D662C993-9F9F-406B-9F30-2A899D0A6612Q33696380-7D09349E-6E74-437D-967E-720D7ED9CA66Q34057324-957F8310-5BC3-495C-A2C0-76BFC56F275BQ34291244-B201F9FF-A29D-44F1-A6C9-58B11B08E241Q34737155-41BFF5FB-94DF-4ECB-8B5D-07751F1DBFCBQ35098179-E6FC36C1-63E8-4438-BBD5-F9093BDDECEAQ37575024-5896D718-95F2-46A1-A239-F8D7B50F311EQ38012391-DAB68054-C7B4-4836-8D80-4842F284B4B7Q38239460-89C34448-58A4-407D-AF4F-BAC8770123B0Q38282740-EE767115-1792-4C01-ABA7-CAD1BE8C5FB9Q38310639-4EDE4897-526E-4CDA-932D-1615344DAFCDQ38843037-4971C805-52D7-44FB-8183-DADE07AA6278Q38919751-9977C705-2DCA-4FAF-AA0B-581951581D08Q40719288-C8A844B5-1F68-41BC-8CDA-211CF41DAEB8Q41587609-DB71F4C9-190E-495A-BD5F-8A1A1F05B87DQ41776452-234FECC2-0F86-49A3-AC46-EF210D4A3B05Q41855274-A0FAD67E-FDAC-4474-BF8E-7174AFB6AE14Q41902616-60F7A7E6-D7AC-480A-A508-62B0FC274375Q41921688-685659E0-EE08-44B9-9799-0E8BDC8DCBA3Q42109713-27B1B93E-F9EC-4132-BA64-5C3271C0DEB9Q42110109-953332DC-8C7A-4073-9117-933C1B0BC0D3Q42110968-622F25A9-4D15-4BDA-A3C7-F12321BBCDF4Q42358800-A8CD5FF6-642F-4260-BC7D-882AA1732C7AQ42905367-13357158-CFF6-4A04-A121-ACBEE99FC5B3Q50420166-3A5605E5-11A2-48B1-94BC-7DB762E262D9
P2860
Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem
@en
Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem
@nl
type
label
Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem
@en
Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem
@nl
prefLabel
Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem
@en
Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem
@nl
P2093
P2860
P356
P1476
Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem
@en
P2093
Hiroko Murakami-Kuroda
Keiichi Hiramatsu
Longzhu Cui
Yuki Katayama
P2860
P304
P356
10.1128/AAC.00834-08
P407
P577
2009-05-18T00:00:00Z